Leukotriene and prostaglandin production after infusion of tumour necrosis factor in man.
Tumor necrosis factor-alpha is believed to be an important mediator of endotoxaemia and septic shock, the effects of which are thought to be mediated through the generation of cysteinyl-leukotrienes, thromboxane A2 and other prostanoids. We have investigated the production of these eicosanoids and also that of prostacyclin in vivo after infusion of tumor necrosis factor-alpha into 4 subjects with a chronic hepatitis B virus infection. This resulted in plasma TNF levels considerably greater than those observed in septic shock. Urinary excretion rate of leukotriene E4 increased by 2 to 3-fold in all subjects by 8 h following TNF infusion. Urinary excretion of thromboxane B2 and 6-oxo-prostaglandin F1 alpha, however, increased in the first 4 h in 3/4 subjects by 2 to 40-fold and returned towards baseline by 8 h. Excretion of the hepatic metabolite, 2,3-dinor 6-oxo-prostaglandin F1 alpha, increased in all subjects (2 to 4-fold at 4h). We conclude that there is increased production of cysteinyl leukotrienes, thromboxane A2 and prostacyclin after infusion of tumour necrosis factor into man.
Moore
K P
KP
Liver Unit, King's College School of Medicine and Dentistry, London, UK.
Sheron
N
N
Ward
P
P
Taylor
G W
GW
Alexander
G J
GJ
Williams
R
R
D000328:Adult; D011464:Epoprostenol / Q000378:metabolism* / Q000652:urine; D006509:Hepatitis B / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D017999:Leukotriene E4; D008297:Male; D008875:Middle Aged; D013189:SRS-A / Q000031:analogs & derivatives* / Q000652:urine; D013928:Thromboxane A2 / Q000378:metabolism* / Q000652:urine; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D013189:SRS-A; D014409:Tumor Necrosis Factor-alpha; D013928:Thromboxane A2; D017999:Leukotriene E4; D011464:Epoprostenol